The Line

In the latest episode of The Line Podcast, Matt Gurney returns from a leave to care for his wife and wonders if he’s missed anything over the last two weeks. Turns out he has. It’s his first chance to sit down with Jen Gerson and talk about the Alberta referendum, and Jen — finally having gotten some sleep — offers her concluding thoughts on … all that. Matt gives his reactions and asks Jen a fairly basic question: what, exactly, was the point of the whole exercise? They agree that Danielle Smith doesn’t come out of it looking particularly good. They a...

In this episode of On The Line, host Jen Gerson speaks with Patrick Lennox, author of On Treason, a new book examining the moral and political consequences of betraying one's own country. Their conversation focuses on Alberta's separatist movement, its reported efforts to secure American recognition for a future independent state, and why Lennox believes the movement represents something more troubling than ordinary regional grievance politics.

This episode is brought to you by BioCanRx. We've been partnering with federally-funded Canadian not-for-profit BioCanRx to learn how made-in-Canada immunotherapies offer new ways to beat cancer. This month we’re ad...

In the latest episode of The Line Podcast, Jen Gerson is joined by Andrew Potter to discuss Alberta's looming separation referendum, Canada's increasingly complicated relationship with American politics, and whether Pierre Poilievre has any realistic plan to get the Conservatives back in the game.

This episode is brought to you by BioCanRx. We’ve been partnering with federally-funded Canadian not-for-profit BioCanRx to learn how made-in-Canada immunotherapies offer new ways to beat cancer. This month we’re addressing common questions, like: are there better ways to manufacture therapies?

A groundbreaking approach that streamlines new therapy production is “...

In today’s episode of On The Line, Gregory Jack, Senior Vice President of Public Affairs at Ipsos Canada, joins Matt Gurney to discuss the growing list of challenges facing Prime Minister Mark Carney — and, for a change, almost none of them have anything to do with Donald Trump or the United States.

This episode is brought to you by BioCanRx. We've been partnering with federally-funded Canadian not-for-profit BioCanRx to learn how made-in-Canada immunotherapies offer new ways to beat cancer. This month we’re addressing common questions, like: are there better ways to manufacture therapies?

A grou...

In this episode of On The Line, Jen Gerson speaks with Corey Hogan, Liberal MP for Calgary Confederation, about Alberta’s separatist referendum, the federal government’s changing approach to the province, and whether Ottawa’s newfound enthusiasm for getting major projects built represents a substantive shift or simply a change in political messaging.

This episode is brought to you by BioCanRx. We've been partnering with federally-funded Canadian not-for-profit BioCanRx to learn how made-in-Canada immunotherapies offer new ways to beat cancer. This month we’re addressing common questions, like: can I get immunotherapy as a first line treatment for canc...

In the latest episode of The Line Podcast, recorded on October 2nd, 2026, Matt Gurney and Jen Gerson begin with the announcement of the new Pacific Link pipeline, unveiled by Prime Minister Mark Carney alongside Alberta Premier Danielle Smith. Your hosts are struck by just how much Carney increasingly sounds like a spiritual — and even political — successor to Stephen Harper or Jason Kenney, rather than Justin Trudeau. That also fits with some of what The Line has been hearing about how these various gentlemen view each other.

This episode is brought to you by Fractional Execs Canada. Need help...

In this episode of On The Line, host Matt Gurney is joined by Stephanie Levitz of The Globe and Mail’s parliamentary bureau to tackle four big questions about life in Ottawa under prime minister Mark Carney.

This episode is brought to you by BioCanRx. We've been partnering with federally-funded Canadian not-for-profit BioCanRx to learn how made-in-Canada immunotherapies offer new ways to beat cancer. This September we're focusing on the "made-in-Canada" part.

Unlike other G7 nations, Canada lacks an anchor company and patient capital with pockets deep enough to pay for the lengthy process of...

In the latest episode of The Line Podcast, Matt Gurney and Jen Gerson begin with some news close to home: The Line gets hacked! Well, almost. Luckily, our defences held. Unfortunately, the list of people who might want to hack us is longer than we'd like. We piss a lot of people off.

This episode is brought to you by Cameco. Canada is entering a decisive decade for energy, and the nuclear reactor we choose now matters. Incomplete designs carry real risk of delays and cost overruns, and we cannot afford to spend years designing a reactor...

In this episode of On The Line, Jen Gerson checks in with Greenland and Europe. Canadians seem increasingly open to closer ties with non-U.S. Western allies — but what do those allies think about us?

This episode is brought to you by BioCanRx. We've been partnering with federally-funded Canadian not-for-profit BioCanRx to learn how made-in-Canada immunotherapies offer new ways to beat cancer. This September we're focusing on the "made-in-Canada" part. One way to leverage existing Canadian government investments in biomanufacturing would be to make it easier for Canadian innovators to develop their discoveries into therapies here in Canada. Asi...

In the latest episode of The Line Mega Productivity Podcast, recorded on September 18th, 2026, prospective associate EU members Matt Gurney and Jen Gerson begin with Prime Minister Mark Carney’s trip to the continent. The reception was remarkably warm, as Canada and Europe explore a much closer strategic relationship. 

This episode is brought to you by Cameco. Canada is entering a decisive decade for energy, and the nuclear reactor we choose now matters. Incomplete designs carry real risk of delays and cost overruns, and we cannot afford to spend years designing a reactor before construction begins. That is...

In this episode of On The Line, host Matt Gurney is joined by Kent Fellows, Associate Professor of Economics at the University of Calgary’s School of Public Policy, for a conversation about game theory, the trade war, and the challenge of getting Canada’s economy moving again. Plus, a very special guest with a special announcement. See more on that below.

This episode is brought to you by BioCanRx. We've been partnering with federally-funded Canadian not-for-profit BioCanRx to learn how made-in-Canada immunotherapies offer new ways to beat cancer. This September we're focusing on the "made-in-Canada" part.Federal and...

In the latest episode of The Line Podcast, recorded on September 11th, 2026, Matt Gurney and Jen Gerson begin by marking the 25th anniversary of the 9/11 terrorist attacks. They reflect on how profoundly America changed after that morning, how the world changed with it, and how the media environment has transformed in the quarter-century since. They also consider how an attack on that scale would be covered today. Their conclusion? Worse. Much worse.

This episode is brought to you by Cameco. Canada is entering a decisive decade for energy, and the nuclear reactor we choose now matters. Incomplete designs...

In this episode of On The Line, Jen Gerson speaks with Ronnen Harary, co-founder of Spin Master, the Canadian company behind some of the world’s most successful toys and entertainment franchises, including PAW Patrol.

This episode is brought to you by BioCanRx. We've been partnering with federally-funded Canadian not-for-profit BioCanRx to learn how made-in-Canada immunotherapies offer new ways to beat cancer. This September we're focusing on the "made-in-Canada" part. Since 2015 BioCanRx has supported the Canadian-Led Immunotherapies Collaborative, or CLIC, in building a truly Canadian pipeline so Canadian patients don't have to wait for cancer therapies developed elsewhere to...

In the latest episode of The Line Podcast, Jen Gerson speaks with Bloomberg senior White House correspondent Josh Wingrove about the collapse of the Canada–U.S. trade deal, the politics behind it, and why Canadians and Americans increasingly seem to be talking past each other.

This episode is brought to you by Cameco. Canada is entering a decisive decade for energy, and the nuclear reactor we choose now matters. Incomplete designs carry real risk of delays and cost overruns, and we cannot afford to spend years designing a reactor before construction begins. That is why Cameco believes th...

In this episode of On The Line, host Matt Gurney is joined by two guests for conversations about political chaos on the west coast and why Canada may need to start thinking very differently about its maritime security.

This episode is brought to you by BioCanRx. Over the summer we partnered with federally-funded Canadian not-for-profit BioCanRx to learn how made-in-Canada immunotherapies offer new ways to beat cancer. This September, we want to better understand the "made-in-Canada" part. Many drugs discovered in Canada leave to be developed and commercialized in the United States –– with the benefits accruing there. Completely made...

In the latest episode of The Line Podcast, recorded on August 28th, 2026, Matt Gurney and Jen Gerson begin with the rapidly escalating Canada-U.S. trade war, which somehow managed to get very stupid, very quickly. Ontario Premier Doug Ford told Donald Trump to kiss his ass; Trump responded by signing an executive order renaming Lake Ontario “Lake America.” Your hosts discuss just how weird this confrontation could get—and whether what we're watching now is merely the opening phase of something much longer and more serious.

This episode is brought to you by Cameco. In nuclear energy, timeli...

In this episode of On The Line, Jen Gerson sits down with Brian Dijkema, president of Cardus Canada, to discuss a new Department of National Defence directive that would move military chaplaincy away from explicit religious language, symbols and prayer in favour of more generic forms of “spiritual reflection.”

This episode is brought to you by BioCanRx. Through our partnership with federally-funded Canadian not-for-profit BioCanRx this summer, we’re talking about potential solutions for the problems that are limiting Canada’s ability to domestically develop new drugs, especially immunotherapies for cancer. Today: new methods for biomanufacturing. 

Immunot...

In the latest episode of The Line Podcast, recorded on August 21st, 2026, Matt Gurney joins remotely from Chicago as he makes his way home to Canada after a family event. Sorry, elbows uppers.

This episode is brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That’s why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are se...

In this episode of On The Line, host Matt Gurney is joined by two guests for conversations about service, sacrifice, and Canada’s place in the world.

This episode is brought to you by BioCanRx. Through our partnership with federally-funded Canadian not-for-profit BioCanRx this summer, we’re talking about potential solutions for the problems that limit Canada’s ability to domestically develop new drugs, especially immunotherapies for cancer. Today: Canada’s biomanufacturing capacity. A biomanufacturing industry, like any other industry, does not appear at the swipe of a bureaucrat’s pen. Simply allocating money to a new economic de...

In the latest episode of The Line Podcast, recorded on August 14th, 2026, Matt Gurney and Jen Gerson begin with a lengthy discussion of the state of the Canada–U.S. trade war. 

This episode is brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That’s why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about build...

In this episode of On The Line, host Jen Gerson sits down with Jared Wesley and Ken Boessenkool, two members of the Lead Not Leave initiative, for a conversation about the current state of Alberta separatism and the province’s uncertain political future.

This episode is brought to you by BioCanRx, a federally-funded Canadian not-for-profit. This summer, BioCanRx and The Line have been talking about potential solutions for the problems that are limiting Canada’s ability to domestically develop new drugs, especially immunotherapies for cancer. We ask a lot of Canadian cancer researchers. The work required to discover new...

In the latest episode of The Line Podcast, recorded on August 7th, 2026, Matt Gurney is joined by guest host Scott Stinson, filling in for Jen Gerson. They begin with the latest twists in Canada-U.S. relations, asking just how much Prime Minister Mark Carney can concede to the Americans before the political costs become too high at home. Both hosts suspect the answer is probably more than many Canadians would expect. They also discuss how fortunate Carney is to be making these decisions while facing relatively weak opposition, with Pierre Poilievre enduring another difficult week. Matt explains why the...

In this episode of On The Line, host Matt Gurney is joined by two guests for conversations about two of the West's most pressing security challenges: military readiness and cyber defence.

This episode is brought to you by BioCanRx, a Canadian not-for-profit working to help Canadian researchers and companies develop new drugs, especially immunotherapies for cancer.

A key challenge for Canada will be familiar to anyone trying to grow a business here: we have some of the brightest people in the world, we just can’t keep enough of them. Canada is home to researchers ma...

In the latest episode of The Line Podcast, recorded on July 31st, 2026, Matt Gurney and Jen Gerson begin by asking whether Canada's governments are actually prepared to make the sacrifices required to defend the country's interests. Both come away disappointed. Matt points to the federal government's decision to block the expansion of an airport in the Toronto area because it was locally controversial and could complicate an upcoming Liberal byelection. If a government isn't willing to risk losing even a single seat to get important things done, Matt argues, then it's never going to get important things done.

<...

For decades, Canada has enjoyed the benefits of NATO while spending comparatively little on its own military. That era may be coming to an end.

This episode is brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network dedicated to cutting edge cancer immunotherapy research that they’re helping Canadian researchers bring from labs to patients in clinical trials –– all in Canada.

If a drug is discovered in a Canadian lab, and conducts successful clinical trials in Canada, there’s a chance it will be launched in Canada. So how do we get more drugs ou...

In the latest episode of The Line Podcast, recorded on July 24th, 2026, hosts Matt Gurney and Jen Gerson set out with the ambitious goal of keeping each segment to a specific, fixed time. 

They do not succeed.

This episode is brought to you by BioCanRx, Ia federally-funded Canadian not-for-profit research network dedicated to cutting edge cancer immunotherapy research that they’re helping Canadian researchers bring from labs to patients in clinical trials –– all in Canada.

If a drug is discovered in a Canadian lab, and conducts successful clinical trials in Canada...

In the latest episode of The Line Podcast, recorded on July 17th, 2026, Matt Gurney and Jen Gerson keep things refreshingly brief as both are juggling family matters. They begin with Jen's unsuccessful attempt to achieve cottage zen, as she unloads on the latest complaints from American politicians about wildfire smoke drifting south from Canada. Both hosts independently arrive at the same tongue-in-cheek solution: if the Americans don't stop griping, Canada should simply schedule its forest fires for days when the wind is blowing south. (They're kidding. Mostly.) They also discuss Donald Trump's latest bizarre speech and the increasingly revealing...

In this episode of On The Line, host Matt Gurney sits down with Reece Martin, transit and transportation expert and new media entrepreneur, for a conversation about infrastructure, public policy, and how an online passion project turned into a career.

This episode is brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network focused on cutting-edge cancer immunotherapy research that they’re helping Canadian researchers bring from labs to patients in clinical trials –– all in Canada.  

A new treatment for your cancer has been approved. Can you get it? Maybe, maybe not. Canada isn’t just on...

In the latest episode of The Line Podcast, recorded on July 10, 2026, Matt Gurney and Jen Gerson begin with a discussion of a recent Wall Street Journal piece highlighting Prime Minister Mark Carney’s role in pulling Europe back toward a more realistic strategic footing and away from its longstanding dependence on the United States. Canada, and Carney in particular, appear to be taking an unexpectedly prominent leadership role. Your hosts wonder what Washington’s response will be, and whether the White House will decide that Canada needs to be reminded who’s boss.

This episode is brought to you...

In this episode of On The Line, host Jen Gerson is joined by Andrew Leach, noted energy and environmental economist and professor of economics and law at the University of Alberta, for a conversation about Canadian energy policy at a pivotal moment.

This episode is brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network bringing cutting edge cancer immunotherapy research from Canadian labs to patients in clinical trials –– all in Canada.

A drug that can treat your cancer is being tested in a Canadian clinical trial, but can you access it...